Ticker

Marijuana stock investors are still in a position where volatility and speculation control the outcome. Especially with all the laws and regulatory changes that have transformed the cannabis industry. All of which has an impact on how the public sector behaves. When an investor speculates, whether for better or worse, it can lead to others following suit, and this typically creates more momentum for the sector as a…

Cronos Group (NASDAQ: CRON - Get Free Report) and Kiora Pharmaceuticals (NASDAQ: KPRX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation. Institutional and Insider Ownership 8.7% of Cronos

The Canadian cannabis sector continues to evolve in 2026, even as volatility remains elevated. Total Canadian cannabis sales have steadily increased in recent years, showing consistent demand growth. However, pricing pressure and competition continue to challenge margins across the industry. Still, leading companies are adapting through international expansion, scale in retail, and diversification. As a result,…

The cannabis industry has made a tremendous impact on the world. From being once a taboo subject to now a well-respected and much more accepted industry. Even the thought of what may happen to a legal operator could shape the way marijuana stock investors think. At one point during the green rush, the fear of what could happen with no federal reform would shift how the market reacted. But as of 2026, those fears and…

Shares of Cronos Group CRON have staged a strong recovery over the past year. The Canada-based cannabis operator's shares have risen 46% in the said time frame, significantly outperforming the industry, as shown in the chart below.